Prostate Cell News Volume 2.27 | Jul 29 2011

    0
    25

    Prostate Cell News 2.27, July 29, 2011

         In this issue: Science News | Current Publications | Industry News | Policy News | Events
    Cell Therapy News on Facebook  Prostate Cell News on Twitter

    TOP STORY
    Dihydrotestosterone Synthesis Bypasses Testosterone to Drive Castration-Resistant Prostate Cancer
    Researchers show that the dominant route of dihydrotestosterone (DHT) synthesis in castration-resistant prostate cancer bypasses testosterone, and instead requires 5α-reduction of androstenedione by steroid-5α-reductase isoenzyme-1 to 5α-androstanedione, which is then converted to DHT. [Proc Natl Acad Sci USA]

    RSGRoboSep_645x110-WatchVid

    SCIENCE NEWS
    UT Southwestern Scientists Discover New Pathway to Potential Therapies for Advanced Prostate Cancer
    Researchers have narrowed the potential drug targets for advanced prostate cancer by demonstrating that late-stage tumors are driven by a different hormonal pathway than was thought previously. [Press release from the University of Texas (UT) Southwestern Medical Center discussing online prepublication in Proceedings of the National Academy of Sciences USA]

    ON144-FreeTShirt_645x110

    CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

    LABORATORY RESEARCH

    A Functional Variant at a Prostate Cancer Predisposition Locus at 8q24 Is Associated with PVT1 Expression
    Researchers examined candidate functional variants of a haplotype block at 8q24 encompassing the two independent risk alleles for prostate and breast cancer, rs620861 and rs13281615. [PLoS Genet]

    Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer
    Researchers report that taxanes inhibit ligand-induced androgen receptor (AR) nuclear translocation and downstream transcriptional activation of AR target genes such as PSA. [Cancer Res]

    Quantitative Glycoproteomic Analysis of OCT-Embedded Frozen Tissues Identifies Glycoproteins Associated with Aggressive Prostate Cancer
    In this study, researchers aim to identify glycoproteins associated with aggressive prostate cancer using optimal cutting temperature (OCT)-embedded frozen tissues obtained from patients with known clinical outcome. [Anal Chem]

    Characterization of the Phosphoproteome in Androgen-Repressed Human Prostate Cancer Cells by Fourier Transform Ion Cyclotron Resonance Mass Spectrometry
    In this study, researchers apply state-of-the-art mass spectrometry methods to investigate the phosphoproteome profiles in androgen-repressed human prostate cancer cells. [J Proteome Res]

    Conditional Expression of the Androgen Receptor Induces Oncogenic Transformation of the Mouse Prostate
    Researchers demonstrated for the first time that conditional activation of transgenic androgen receptor expression by Osr1 promoter induces prostate tumor formation in mice. [J Biol Chem]

    Nuclear Transport Signals Control Cellular Localization and Function of Androgen Receptor Cofactor p44/WDR77
    In this study, researchers observed distinct subcellular location of p44/WDR77 during prostate development. [PLoS One]

    Metabolomic Profiling Reveals a Role for Androgen in Activating Amino Acid Metabolism and Methylation in Prostate Cancer Cells
    Researchers used unbiased metabolomic profiling coupled with enrichment-based bioprocess mapping to obtain insights into the biochemical alterations mediated by androgen in prostate cancer cell lines. [PLoS One]

    Androgen Suppresses Proliferation of Castration-Resistant LNCaP 104-R2 Prostate Cancer Cells via Androgen Receptor, Skp2, and c-Myc
    Researchers study the molecular mechanism lying underneath the androgenic regulation of prostate cancer cell proliferation. [Cancer Sci]

    Androgen Deprivation Therapy Affects BCL-2 Expression in Human Prostate Cancer
    Researchers studied BCL-2 expression in vivo in prostate cancer tissues obtained from patients who underwent radical prostatectomy after neoadjuvant androgen deprivation therapy, by Northern and Western blot analysis, and immunohistochemistry. [Int J Oncol]

    CLINICAL RESEARCH

    ERG Status is Unrelated to Prostate Specific Antigen Recurrence in Radically Operated Prostate Cancer in the Absence of Anti-Hormonal Therapy
    The aim of this study was to determine whether clinical differences exist between ERG-positive and ERG-negative cancers in surgically treated patients not exposed to anti-hormonal therapy. [Clin Cancer Res]

    Single-Fraction High Dose Rate Brachytherapy and Hypofractionated External Beam Radiation Therapy in the Treatment of Intermediate-Risk Prostate Cancer – Long Term Results
    Scientists present the long-term results of a cohort of patients with intermediate-risk prostate cancer (PC) treated with single-fraction high-dose-rate brachytherapy combined with hypofractionated external beam radiation therapy. [Int J Radiat Oncol Biol Phys]

    Association of Census Tract-Level Socioeconomic Status with Disparities in Prostate Cancer-Specific Survival
    Researchers analyzed whether census tract-level socioeconomic status at diagnosis is a prognostic factor in men with prostate cancer and helps explain racial/ethnic disparities in survival. [Cancer Epidemiol Biomarkers Prev]

    A Phase II Clinical Trial of Neoadjuvant Ketoconazole and Docetaxel Chemotherapy Before Radical Prostatectomy in High Risk Patients
    Researcher conducted a phase II clinical trial examining the combination of ketoconazole and docetaxel in the neoadjuvant setting before radical prostatectomy. [J Urol]

    Prostate Specific Antigen Velocity per Prostate Volume: A Novel Tool for Prostate Biopsy Prediction
    Researchers investigated which variables were exact to predict prostate biopsy using univariate and multivariate analyses, and assessed the diagnostic performance using the receiver operating characteristic curve. [Urology]

    INDUSTRY NEWS

    Adamis Reports APC-300 Kills Human Prostate Cancer Cells
    Adamis Pharmaceuticals Corporation announced that in addition to activity in pancreatic cancer and its multiple modes of action, APC-300 significantly inhibits the growth of prostate cancer cells. [Business Wire]

    XGEVA® (Denosumab) Granted Marketing Authorization in the European Union
    Amgen announced that the European Commission has granted marketing authorization for XGEVA® (denosumab) for the prevention of skeletal-related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumors. [Amgen Press Release]

    McKee Cancer Center Expansion Will Offer Enhanced Radiation Treatments
    McKee Medical Center has announced plans to invest more than $9 million to expand the McKee Cancer Center with new services and technology to improve patient care. [Banner Health Press Release]

    Jupiter Medical Center and Scripps Research Institute Collaborate to Increase Understanding of Cancer
    In a first for both institutions, Jupiter Medical Center and The Scripps Research Institute, are teaming up to conduct research on human cancer tissue. [Jupiter Medical Center Press Release]

    POLICY NEWS

    National Institutes of Health (United States)

    Food and Drug Administration (United States)

    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)

    EVENTS

    NEW 2nd International Conference on Stem Cells and Cancer 
    October 15-18, 2011 
    Pune, India 

    NEW AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications 
    November 12-16, 2011 
    San Francisco, United States 

    JOB OPPORTUNITIES

    Lab Technologist – Tissue Culture (STEMCELL Technologies)

    Research and Development Technologist, hPSC Media (STEMCELL Technologies)

    Scientist (iPSC) (STEMCELL Technologies)

    Postdoctoral Position – Endocrinology of Prostate Cancer (Baylor College of Medicine)

    Prostate Cancer Scientist (McGill University Health Centre) 

    Recruit Top Talent
    Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

    Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

    Visit here to post your career opportunities.

    Have we missed an important article or publication in Prostate Cell News? Click here to submit!

    Comments or Suggestions? Email info@connexoncreative.com with your feedback.

    Learn more about Prostate Cell News: Archives | Events | Contact Us